Clinical and paphogenical aspects of kidney damage in obesity (review)

Obesity is one of actual medico-social problems of modern society. Rapid growth of the persons suffering from excess mass of a body, defines relevance of this problem. Obesity leads to progressive injury of kidneys through a set of mechanisms. Use of early biomarkers of pathology of kidneys at obesity with an assessment of level of indicators of a lipid, carbohydrate exchange, insulin resistance, serum leptin and adiponectin are perspective for diagnostics of renal defeat at obesity in children.

obesity, kidney, leptin, adiponectin, tumor necrosis factor - alpha, renin-angiotensin system, interaglomerulus hypertension, podocyte

1. Бутрова СА, Дзгоева ФХ. Висцеральное ожирение -ключевое звено метаболического синдрома. Ожирение и метаболизм 2004; (1): 10-16 [Butrova SA, Dzgoeva FH. Visceral'noe ozhirenie - kljuchevoe zveno metabolicheskogo sindroma. Ozhirenie i metabolizm 2004; (1): 10-16]

2. Вялкова АА, Николаева СН, Лебедева ЕН и др. Характеристика липидного обмена при ожирении у детей с нефропатиями. Материалы III научно-практическая конференция «Педиатрия и детская хирургия в Приволжском федеральном округе». Казань, 2006;107-108 [Vjalkova AA, Nikolaeva SN, Lebedeva EN i dr. Harakteristika lipidnogo obmena pri ozhirenii u detej s nefropatijami. Materialy III nauchno-prakticheskaja konferencija «Pediatrija i detskaja hirurgija v Privolzhskom federal’nom okruge». Kazan’, 2006; 107-108]

3. Гинзбург ММ, Козупица ГС. Значение распределения жира при ожирении Пробл эндокр 1996; 42(3): 42-46 [Ginzburg MM, Kozupica GS. Znachenie raspredelenija zhira pri ozhirenii Probl jendokr 1996; 42(3): 42-46]

4. Дедов ИИ, Мельниченко ГА, Романцова ТИ. Патогенетические аспекты ожирения. Ожирение и метаболизм 2004; (1): 3-9 [Dedov II, Mel’nichenko GA, Romancova TI. Patogeneticheskie aspekty ozhirenija. Ozhirenie i metabolizm 2004; (1): 3-9]

5. Кутырина И., Краснова Е., Федорова Е., Фомин В. Поражение почек при ожирении: клинические, патогенетические и терапевтические аспекты. Врач 2005; (6):6-9 [Kutyrina I., Krasnova E., Fedorova E., Fomin V. Porazhenie pochek pri ozhirenii: klinicheskie, patogeneticheskie i terapevticheskie aspekty. Vrach 2005; (6):6-9]

6. Ogden CL , Yanovski SZ, Carroll MD, Flegal KM The epidemiology of obesity. Gastroenterology 2007; 132: 2087-2102

7. Мухин НА, Балкаров ИМ, Моисеев СВ и др. Хронические прогрессирующие нефропатии и образ жизни современного человека Тер арх 2004; (9): 5-11 [Muhin NA, Balkarov IM, Moiseev SV i dr. Hronicheskie progressirujushhie nefropatii i obraz zhizni sovremennogo cheloveka Ter arh 2004; (9): 5-11]

8. Мухин НА, Шоничев ДГ, Балкаров ИМ и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек Тер. арх 1999; (6): 12-24 [Muhin NA, Shonichev DG, Balkarov IM i dr. Formirovanie arterial‘noj gipertonii pri uratnom tubulointersticial‘nom porazhenii pochek Ter. arh 1999; (6): 12-24]

9. Kambham N, Markowitz G, Valeri A et al. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001;59: 1498-1509

10. Николаева СН, Лебедева ЕН, Вялкова АА и др. Клиническая оценка уровня лептина и инсулина в крови у детей с ожирением. Совр вопросы педиатрии 2007; (5):485-486 [Nikolaeva SN, Lebedeva EN, Vyalkova AA i dr. Klinicheskaja ocenka urovnja leptina i insulina v krovi u detej s ozhireniem. Sovr voprosy pediatrii 2007; (5):485-486]

11. Мухин НА, Арутюнов ГП, Фомин ВВ. Альбуминурия - маркер поражения почек и риска сердечно-сосудистых осложнений Клин нефр 2009;(1): 5-10 [ Muhin NA, Arutjunov GP, Fomin VV. Al’buminurija - marker porazhenija pochek i riska serdechno-sosudistyh oslozhnenij Klin nefr 2009;(1): 5-10]

12. Сигитова ОН, Бикмухамметова ЭИ, Надеева РА. Микроальбуминемия - диагностическое и прогностическое значение при артериальной гипертонии. Арт гипертенз 2009;15(6):627-632 [Sigitova ON, Bikmuhammetova JeI, Nadeeva RA. Mikroal’buminemija - diagnosticheskoe i prognosticheskoe znachenie pri arterial’noj gipertonii. Art gipertenz 2009;15(6):627-632]

13. Papafragkaki DK, Tolis G. Obesity and renal disease: A possible role of leptin. Hormones 2005; 4(2):90-95

14. Сагинова ЕА, Фомин ВВ, Моисеев СВ, Лебедева МВ. Поражения почек при ожирении. Тер арх 2007;(5):88-94 [Saginova EA, Fomin VV, Moiseev SV, Lebedeva MV. Porazhenija pochek pri ozhirenii. Ter arh 2007;(5):88-94 ]

15. Федорова ЕЮ, Кутырина ИМ. Механизмы прогрессирования поражения почек при ожирении. Нефрология и диализ 2006;(2):3-12 [Fedorova EJu, Kutyrina IM. Mehanizmy progressirovanija porazhenija pochek pri ozhirenii. Nefrologija i dializ 2006;(2):3-12]

16. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013 Jan; 33(1):14-22.

17. Praga M, Hernаndez E, Morales E. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant2001;15: 1790-1798

18. Meier-Krieshce HU, Vaghela M, Thambuganipalle R. The effect of body index on long-trem renal allograft survival.Transplan-tation1999;68: 1294-1297

19. Ahima RS. Linking adiponectin to proteinuria. JCI 2008; 118(2): 1619-1622

20. Coresh J. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298:2038-2047

21. Kramer H. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am. J. Kidney Dis. 2005; (46):587-594

22. Villarreal D, Reams G, Freeman RH, Taraben A. Renal effects of leptin in normotensive, hypertensive and obese rats. Am J Physiol 1998; 275: 2056-2060

23. Kohan DE. Endothelins in the normal and diseased kidney. Am. J Kidney Dis 1996; 1: 2-26

24. Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013 Jan; 33(1):2-13.

25. Saxena AK , Chopra R. Renal risk of an emerging epidemic of obesity: the role of adipocyte-derived factors. Nephrol Dial Transplant 2004; 33: 11-20

26. van Stijn CM, Kim J, Barish GD. Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS One. 2014 Jan 22; 9 (1):e86404.

27. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002;39: 1-11

28. Wolf G. Obesity and Renal Disease: Introduction. Semin Nephrol. 2013 Jan; 33(1):1.

29. Han DC, Isono M, Chen S. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001; 59:1315-1323

30. Hong SW, Isono M, Chen S et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/ db mouse.Am J Pathol 2001;158: 1653-1663

31. Allessi MC, Peiretti F, Morange P. et al. Production of plasminogen activator inghibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes1997; 46: 860-867

32. Engeli S, Negel R, Sharma AM. Pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000; 35: 1270- 1276

33. Rüster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. Semin Nephrol. 2013 Jan; 33(1):44-53

34. Baud L, Fouqueray B, Amrani PC. Tumor necrosis factor alpha and mesangial cells Kidney Int 1992; 41: 600-603

35. Stenvinkel P. Leptin and its clinical implications in chronic renal failure Miner Electrolyte Metab 1999;25: 298-302

36. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome.J. Am. Soc. Nephrol. 2006;17(4, 2):S81-S85

37. Sharma K, Considini RV, Beckie M. et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Intern 1997; 51:1980-1985

38. Nasrallah MP, Ziyadeh FN. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephrol. 2013 Jan; 33(1):54-65.

39. Pistrosch F. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005; 54:2206-2211

40. Miyazaki Y Cersosimo E, Triplitt C, DeFronzo RA. Rosigli-tazone decreases albuminuria in type 2 diabetic patients. Kidney Int 2007;72:1367-1373

41. Pajvani UB Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004;279:12152-12162

42. Bonnet F, Deprele C, Sassolas A. et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA-nephritis.Am J Kidney Dis 2001; 37: 720-727

43. Siddiqi FS, Advani A. Endothelial-Podocyte Crosstalk: The Missing Link Between Endothelial Dysfunction and Albuminuria in Diabetes. Diabetes 2013;.62 (11): 3647-3655

44. Lee MJ. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007;292:F617-F627

45. Henegar J, Bigler S, Henegar L. et al. Functional and structural changes in the kidney in the early stages of obesity. Am J Soc Nephrol 2001;12: 1211-1217

46. Sharma K, McCue P, Dunn S. Diabetic kidney disease in the db/db mouse. Am J Renal Physiol 2003; 284: 1138-1144

47. Verani RR, Grone EF. The role of lipids in nephrosclerosis and glomerulosclerosis Atherosclerosis 1994; 107: 1-13

48. Sharma K. Adiponectin regulates albuminuria and podocyte function in mice. J. Clin. Invest. 2008; 118:1645-1656

49. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009;76:145-148

50. Kadowaki T. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006;116:1784-1792

51. Nawrocki AR. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 2006; 281:2654-2660

52. Yamauchi T, Nio Y Maki T. et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med.2007;13:332-339

53. Ohashi K. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 2007; 27:1910-1917

54. Ouedraogo R, Gong X Bercins B. et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007;117:1718-1726

55. Yano Y Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes.J Clin Hypertens (Greenwich) 2007; 9:775-782

56. Looker HC. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89:4010-4017

57. Dengel DR, Glodberg AP, Mayuga RS. et al. Insulin resistance, elevated glomerular filtration fraction and renal injury. Hypertension 1996; 28:127-132

58. Наточин ЮВ. Нефрология и фундаментальная наука. Нефрология 2012; 16: 9-21 [NatochinYuV. Nephrologija i fundamental’naja nauka. Nephrologija 2012; 16: 9-21]

59. Смирнов АВ, Шилов ЕМ, Добронравов ВА. Национальные Рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология 2012; 16: 89-115 [Smirnov AV, Shilov EM, Dobronravov VA. National’nye Recommendacii. Chroniches-kaja bolezn’ pochek: osnovnye principy screninga, diagnostiki, profilaktiki i podhody k lecheniju. Nephrologija 2012; 16: 89-115]

60. Wiecek A, Kokot F, Chudek J , Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologists. Nephrol Dial Transplant 2002; 17: 191-195

61. Risheng Y, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab 2013; 2(3): 133-141

62. Stenvinkel P.Adiponectin in chronic kidney disease: a complex and context sensitive clinical situation. Journal of Renal Nutrition.2011; 21(1):82-86

63. Park SH, Carrero JJ, Lindholm B, Stenvinkel P. Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol. 2009 Aug; 72(2):87-96.

64. Jeon WS, Park JW, Lee N et al. Urinary adiponectin concentration is positively associated with micro- and macrovascular complications. Cardiovasc Diabet 2013; 12:137